Title: Machine-learning prediction of hypertensive disorders of pregnancy based on home blood pressure monitoring

Short title: Machine-learning prediction of HDP based on HBPM
[48/50 characters including spaces]

Authors:

Makito Oku (PhD)[1], Shuntaro Ohno (PhD)[2], Hirohito Metoki (MD, PhD)[3,4], Eri Arai (MD)[5], Mika Ito (MD, PhD)[5], Arihiro Shiozaki (MD, PhD)[5], Akitoshi Nakashima (MD, PhD)[5], Noriyuki Iwama (MD, PhD)[6], Rie Tsuchida[3], Satoshi Yoneda (MD, PhD)[5], Noriko Yoneda (MD, PhD)[5], Sayaka Tsuda (MD, PhD)[5], Michihiro Satoh (PhD)[3], Takahisa Murakami (PhD)[3], Shingo Tanigawara (MD, PhD)[7], Kazuhiko Hoshi (MD, PhD)[7], Kohei Tanaka (MD, PhD)[7], Masaaki Yamada (MD, PhD)[7], Shigeru Saito (MD, PhD)[8]

Research Center for Pre-Disease Science, University of Toyama, Toyama, Japan

Research Center for Idling Brain Science, University of Toyama, Toyama, Japan

Division of Public Health, Hygiene and Epidemiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toyama, Toyama, Japan

Center for Maternal and Perinatal Medicine, Tohoku University Hospital, Sendai, Miyagi, Japan

Suzuki Memorial Hospital, Iwanuma, Japan

University of Toyama, Toyama, Japan

Corresponding author: Shigeru Saito (email: s30saito@med.u-toyama.ac.jp; address: University of Toyama, Toyama, 930-8555, Japan)

Word counts: 5932/6000

Abstract [228/250 words]

Background:

Hypertensive disorders of pregnancy (HDP) cause adverse maternal and fetal outcomes, and establishing an early prediction method for HDP is needed. Existing methods based on serum markers require blood sampling. Therefore, we aimed to develop and validate a noninvasive machine-learning prediction method for HDP based on home blood pressure monitoring (HBPM).

Methods:

In a development cohort, HBPM data from 443 pregnant women including 65 HDPs were divided into training data (n=365) and test data (n=78) to develop a logistic regression-based prediction model. Normal blood pressure variations depending on season and gestational age were subtracted. At each time point, four features were calculated for the last four weeks of data: average systolic blood pressure (SBP), average diastolic blood pressure (DBP), correlation coefficient between SBP and DBP, and upward trend of SBP against day. In a validation cohort, HBPM data from 264 pregnant women including 33 HDPs were collected prospectively and used to validate the model.

Results:

The area under the receiver operating characteristic curve was 0.949, 0.884, and 0.845 for the training, test, and validation data, respectively. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.769, 0.889, 0.543, and 0.957 for the development cohort, and 0.758, 0.766, 0.316, and 0.957 for the validation cohort.

Conclusions:

Our machine-learning prediction method for HDP based on HBPM showed high negative predictive values and may contribute to reducing medical consultations.

Abbreviations and Acronyms

- AUC (Area Under the Curve)
- BMI (Body Mass Index)
- BOSHI study (Babies and Their Parents' Longitudinal Observation in Suzuki Memorial Hospital in Intrauterine Period study)
- CI (Confidence Interval)
- DBP (Diastolic Blood Pressure)
- GH (Gestational Hypertension)
- HBP (Home Blood Pressure)
- HBPM (Home Blood Pressure Monitoring/Measurement)
- HDP (Hypertensive Disorders of Pregnancy)
- IQR (Interquartile Range)
- NBP (Normal Blood Pressure)
- NPV (Negative Predictive Value)
- OBP (Office Blood Pressure)
- OBPM (Office Blood Pressure Monitoring/Measurement)
- PE (Preeclampsia)
- PlGF (Placental Growth Factor)
- PPV (Positive Predictive Value)
- SBP (Systolic Blood Pressure)
- sFlt-1 (Soluble Fms-like Tyrosine Kinase-1)

Introduction

Hypertensive disorders of pregnancy (HDP) are hypertension and related symptoms in pregnant women. The HDP incidence is approximately 5-10% of pregnant women [1]. HDP is classified into four subtypes: gestational hypertension (GH), preeclampsia (PE), chronic hypertension, and superimposed preeclampsia [2-5]. Among them, GH and PE are predominant and are characterized by new onset of hypertension after 20 weeks of gestation [6]. PE causes more than 70,000 maternal deaths and more than 500,000 fetal and neonatal deaths worldwide each year [3]. Furthermore, approximately 15-25% of GH cases may progress to PE [7]. Therefore, establishing an early prediction method for PE and GH is needed.

Previous studies have developed prediction algorithms for PE based on biophysical markers including mean arterial pressure and uterine artery pulsatility index, biochemical markers including placental growth factor (PlGF), maternal demographic characteristics, and medical history [8-14]. In addition, the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to PlGF has demonstrated high predictive efficacy [15,16]. The sFlt-1/PlGF test was approved in Japan in July 2021 and in the United States in May 2023. However, a limitation of existing prediction methods is their reliance on serum markers, such as PlGF and sFlt-1, which require blood sampling.

In contrast, home blood pressure monitoring/measurement (HBPM) enables frequent, accurate, and long-term measurements at low cost without white coat effects [17,18]. HBPM is also expected to be a promising technology for HDP screening [2,19,20]. However, no machine-learning model has been developed so far to predict HDP based on HBPM due to the complexity of blood pressure variations during pregnancy.

To resolve this issue, we focused on the Babies and their Parents' Longitudinal Observation in Suzuki Memorial Hospital in Intrauterine Period (BOSHI) study [21-26], a large-scale cohort study of HBPM during pregnancy. The study revealed detailed long-term blood pressure variations depending on season and gestational age in pregnant women [21]. For normal blood pressure (NBP) cases, the population means of both systolic blood pressure (SBP) and diastolic blood pressure (DBP) increased in winter and decreased in summer [21]. In addition, they reached their lowest levels at around 20 weeks of gestation and increased thereafter toward delivery, forming U-shaped curves [21].

Based on these findings, this study aimed to develop and validate a noninvasive and accurate machine-learning prediction method for HDP based on HBPM, incorporating compensation for the seasonal and gestational age-dependent variations.

Materials and Methods

Diagnostic Criteria for Hypertension

Generally, diagnostic criteria for hypertension differ between office blood pressure (OBP) and home

blood pressure (HBP) [18,27,28]. However, there are no widely accepted diagnostic criteria for hypertension in pregnancy regarding HBP [29]. Therefore, OBP criteria were used in this study to define hypertension in pregnancy based on HBP: (1) HBP ≥ 140/90 mmHg was observed twice in a row within 48 hours, or (2) HBP ≥ 160/110 mmHg was observed once. OBP monitoring/measurement (OBPM) at prenatal checkups was used only for reference. Supplementary Figure 1 compares HBP and OBP measured on the same day. When all data were analyzed together, median home SBP and DBP were 2.0 and 2.5 mmHg lower than office SBP and DBP, respectively.

Because PE-related symptoms such as proteinuria could not be diagnosed by the participants themselves, detailed diagnosis by a doctor including HDP subtyping was made at a medical institution.

Study Participants

In the development cohort, we analyzed the dataset of the BOSHI study [21-26], which recruited pregnant women who reserved gave birth at Suzuki Memorial Hospital in Miyagi Prefecture, Japan, from October 2006 to October 2011. Figure 1 shows the flowchart. The total number of participants was 1292 (NBPs: 1051; HDPs: 241). We excluded cases with multiple pregnancy (n=14). We also excluded cases with insufficient HBPM (n=835) defined by: (1) no data within 7 days before hypertension onset or delivery (n=780), (2) less than 14 measurement days after 18 weeks of gestation (n=35), or (3) shorter than 56 days of measurement period including missing values after 11 weeks of gestation (n=20). Finally, the data of 443 participants (NBPs: 378; HDPs: 65) remained and were divided into training data (NBPs: 339; HDPs: 26) and test data (NBPs: 39; HDPs: 39; characteristics matched for age, prepregnancy body weight, height, delivery month, measurement number, and measurement rate).

In the validation cohort, HBPM data were prospectively collected from pregnant women who visited either Toyama University Hospital in Toyama Prefecture, Japan, from October 2021 to December 2023, or Suzuki Memorial Hospital from January 2022 to December 2023. We tried to avoid including pregnant women with multiple pregnancy. The total number of participants was 310 (All: NBPs, 264; HDPs, 46; Toyama: NBPs, 106; HDPs, 25; Miyagi: NBPs, 158; HDPs, 21). We excluded cases with multiple pregnancy (n=1) and induced abortion (n=3). We also excluded cases with insufficient HBPM (n=42) defined by: (1) less than 14 measurement days after 18 weeks of gestation (n=35), or (2) shorter than 56 days of measurement period including missing values after 11 weeks of gestation (n=7). Finally, the data of 264 participants (All: NBPs, 231; HDPs, 33; Toyama: NBPs, 98; HDPs, 21; Miyagi: NBPs, 133; HDPs, 12) remained and were used as validation data.

Data collection

The development cohort data were extracted from the database of the BOSHI study [21-26]. The validation cohort data were collected using automatic cuff-style blood pressure monitors (HCR-7501T,

Omron Healthcare, Japan), provided to each participant to measure her blood pressure every morning and evening at home. The participants were instructed to measure HBP twice per occasion (that is, twice in the morning and twice in the evening) under conditions recommended by the Japanese Society of Hypertension Guidelines for the Management of Hypertension [28]. The measurement data were transmitted to a dedicated app (OMRON connect, Omron Healthcare, Japan) on each participant's smartphone via Bluetooth, sent to a secure cloud service (OMRON connect cloud, Omron Healthcare, Japan) over the Internet, and retrieved by authorized personnel using a dedicated service (B2B Data Services Platform, Omron Healthcare, Japan).

The measurement period of the validation cohort was from study participation (median: 11.9 weeks of gestation) to at least delivery and up to 12 weeks after delivery for follow-up. The measurements after delivery or HDP onset were excluded from the analysis. Supplementary Table 1 shows HBPM statistics. In the validation cohort, the median number of the total measurements per participant was 360.5, and at least one measurement was taken on 86.2% of all days within the measurement period.

Machine-learning prediction method

Supplementary Figure 2 shows steps of the machine-learning method for HDP prediction. First, HBPM data were acquired. Second, normalization was performed, in which normal blood pressure variations depending on season and gestational age were subtracted. Supplementary Figure 3 shows the seasonal and gestational age-dependent variations estimated using HBPM data from 12 to 40 weeks of gestation from 339 NBPs in the development cohort. Combinations of trigonometric functions were used for the seasonal variations, and quadratic functions were used for the gestational age-dependent variations. The adjusted SBP and DBP were rescaled to have standard deviations close to 1. Third, missing values were imputed using linear interpolation, with random noise added to the interpolated values to mimic realistic fluctuations. Fourth, at each time point, four features were calculated for the last four weeks: mean SBP, mean DBP, correlation coefficient between SBP and DBP, and slope of SBP against day. Fifth, the feature values were normalized again. Finally, a weighted summation of the normalized feature values, termed the prediction score, was compared with a threshold. The weights were determined by logistic regression, and the threshold was determined to meet 90% specificity in the training data. If the prediction score was greater than or equal to the threshold, HDP development after the prediction time point was expected.

Statistical Analysis

Statistical analysis was performed with Python version 3.9 (Python Software Foundation, Beaverton, OR, USA). Mann-Whitney U-test and chi-squared test were used for between-group comparisons on numerical and categorical variables, respectively. Data were presented as median and interquartile range (IQR). A p-value less than 0.05 was considered statistically significant. The confidence level for

confidence intervals (CI) was 95%.

Ethical Approval

All procedures of this study were performed in accordance with the 1964 Helsinki Declaration, its later amendments, and the "Ethical Guidelines for Life Science and Medical Research Involving Human Subjects" published by the Ministry of Health, Labour and Welfare of Japan. The Institutional Review Boards of Tohoku University School of Medicine, Tohoku Medical and Pharmaceutical University, and the Hospital Review Board of Suzuki Memorial Hospital approved the BOSHI study protocol. The ethics committee of Toyama University Hospital approved the study protocol with respect to Toyama University Hospital on 2021/4/22 (approval number: R2021021), and the ethics committee of Tohoku Medical and Pharmaceutical University approved the study protocol with respect to Suzuki Memorial Hospital on 2022/1/13 (approval number: 2021-0-015-0001). The study participants gave written informed consent.

Data and Code Availability

The data and source codes generated, analyzed, or used in the current study are available from the corresponding author upon reasonable request.

Results

The baseline characteristics of the participants are shown in Table 1. Overall, the development and validation cohorts exhibited comparable characteristics. The proportion of prepregnancy obesity (defined as BMI $\geq$ 25 kg/m^2 according to the Japanese criterion) was significantly higher in the HDPs compared to the NBPs, both in the development cohort (NBPs: 11.9% (n=45); HDPs: 23.1% (n=15); p=0.025) and the validation cohort (NBPs: 19.5% (n=45); HDPs: 39.4 % (n=13); p=0. 018). Similarly, the median SBP value from the first HBPM was significantly higher in the HDPs compared to the NBPs, both in the development cohort (NBPs: 104.0 (IQR: 98.0-110.0) mmHg; HDPs: 111.0 (IQR: 106.0-117.0) mmHg; p=2.3×10^{-9}) and the validation cohort (NBPs: 99.0 (IQR: 92.0-106.0) mmHg; HDPs: 107.0 (IQR: 99.0-113.0) mmHg; p=0.0010). Furthermore, the median DBP value from the first HBPM was also significantly higher in the HDPs compared to the NBPs, both in the development cohort (NBPs: 63.0 (IQR: 58.0-68.0) mmHg; HDPs: 70.0 (IQR: 65.0-75.0) mmHg; p=3.1×10^{-9}) and the validation cohort (NBPs: 67.0 (IQR: 62.0-72.0) mmHg; HDPs: 75.0 (IQR: 71.0-79.0) mmHg; p=3.0×10^{-5}).

The adverse pregnancy outcomes of the participants are shown in Supplementary Table 2. The median gestational age at delivery was significantly lower in the HDPs compared to the NBPs in the

development cohort (NBPs: 39.9 (IQR: 39.0-40.6) weeks; HDPs: 39.4 (IQR: 38.4-40.1) weeks; p=0.0021). The median of mean SBP during the third trimester was significantly higher in the HDPs compared to the NBPs, both in the development cohort (NBPs: 105.0 (IQR: 100.1-109.8) mmHg; HDPs: 119.3 (IQR: 113.3-123.8) mmHg; p=9.3×10^{-24}) and the validation cohort (NBPs: 104.7 (IQR: 100.2-110.5) mmHg; HDPs: 115.3 (IQR: 110.4-119.3) mmHg; p=3.9×10^{-10}). Similarly, the median of mean DBP during the third trimester was significantly higher in the HDPs compared to the NBPs, both in the development cohort (NBPs: 62.0 (IQR: 58.4-65.9) mmHg; HDPs: 75.1 (IQR: 70.3-77.9) mmHg; p=1.9×10^{-26}) and the validation cohort (NBPs: 67.1 (IQR: 62.6-71.8) mmHg; HDPs: 78.3 (IQR: 74.6-81.0) mmHg; p=3.3×10^{-12}).

Figure 2 shows the receiver operating characteristic curves of the training, test , and validation data. The area under the curve (AUC) values were 0.949 (CI: 0.890-1.000), 0.884 (CI: 0.807-0.961), and 0.845 (CI: 0.759-0.930) for the training, test, and validation data, respectively. In other words, our prediction method consistently showed high AUC values.

Table 2 shows the prediction performance of the proposed method. For the training data, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 0.923 (CI: 0.749-0.991), 0.888 (CI: 0.849-0.919), 0.387 (CI: 0.266-0.519), and 0.993 (CI: 0.976-0.999), respectively. For the test data, sensitivity, specificity, PPV, and NPV were 0.667 (CI: 0.498-0.809), 0.897 (CI: 0.758-0.971), 0.867 (CI: 0.693-0.962), and 0.729 (CI: 0.582-0.847), respectively. We also analyzed all training and test data together because some statistics depend on the balance between the NBPs and HDPs, and the proportion of the HDPs in the test data was 50% due to matching, which was much higher than the original population. For the all data of the development cohort, sensitivity, specificity, PPV, and NPV were 0.769 (CI: 0.648-0.865), 0.889 (CI: 0.853-0.919), 0.543 (CI: 0.436-0.648), and 0.957 (CI: 0.930-0.976), respectively. For the validation data, sensitivity, specificity, PPV, and NPV were 0.758 (CI: 0.577-0.889), 0.766 (CI: 0.706-0.819), 0.316 (CI: 0.216-0.431), and 0.957 (CI: 0.917-0.981), respectively. These results confirmed that our prediction method could consistently exhibit high NPV as well as moderate sensitivity and specificity.

As a sensitivity analysis, we investigated how the prediction performance changes if hypertension was redefined using HBP criteria for the general population: (1) HBP ≥ 135/85 mmHg was observed twice in a row within 48 hours, or (2) HBP ≥ 155/105 mmHg was observed once. Supplementary Table 3 shows prediction performance of the proposed method in the sensitivity analysis. The results did not change much, indicating the robustness of our prediction method.

Table 3 shows the prediction performance of the proposed method for predictions within one week or four weeks. Because the sFlt-1/PlGF ratio is used for predicting the absence of HDP within one week and the occurrence of HDP within four weeks, we focused on NPV within one week and PPV within four weeks. For all data of the development cohort, NPV within one week was 0.996 (CI: 0.996-0.997), and PPV within four weeks was 0.338 (CI: 0.323-0.352). In the validation data, NPV within one week was 0.998 (CI: 0.997-0.998), and PPV within four weeks was 0.168 (CI: 0.154-0.182). These results confirmed that our prediction method consistently showed quite high NPV within one week.

Discussion

In this study, we developed a machine-learning prediction method for HDP based on HBPM in the development cohort and verified its effectiveness in the validation cohort. Our method demonstrated high NPV and moderate sensitivity and specificity across the training, test, and validation data. The high NPV suggests suitability for screening individuals at low risk for HDP, reducing unnecessary medical tests or interventions. In addition, moderate sensitivity and specificity achieved with non-invasive HBPM highlight its potential as a practical and low-cost complement to the existing prediction methods [8-16] that require blood sampling.

Notably, our method has a sufficiently high NPV within one week (development cohort: 0.996; validation cohort: 0.998), which is comparable to that of the sFlt-1/PlGF ratio [15] (its development cohort: 0.989; its validation cohort: 0.993). However, PPV within four weeks of our method (development cohort: 0.338; validation cohort: 0.168) was lower than that of the sFlt-1/PlGF ratio [15] (its development cohort: 0.407; its validation cohort: 0.367). The difference is that our cases involved healthy pregnant women without risk factors, whereas Zeisler et al. [15] studied cases with clinical suspicion of preeclampsia.

One of the strengths of our study is the use of large-scale and high-quality cohort data from the BOSHI study [21-26], which enabled accurate modeling of seasonal and gestational age-dependent blood pressure variations for reliable predictions. Another strength is the validation of our method in a separate multicenter cohort. It has been reported that models developed and tested within the same cohort often exhibit high predictive performance, but their accuracy frequently declines when applied to temporally or geographically distinct external cohorts due to overfitting and limited generalizability [30,31]. Our study addresses this by explicitly quantifying the drop in predictive performance and demonstrating the feasibility and limitations of model transferability across populations.

Moreover, the use of HBPM itself has many advantages [17,18] and has been expected to be useful for HDP prediction [2,19,20]. Hsieh et al. used a machine learning model based on HBPM to predict cardiovascular outcomes in the general adult population [32]. Although previous studies reported the clinical value of HBPM in pregnant women at high risk of HDP [33,34], to our knowledge, this study is the first to demonstrate the effectiveness of HBPM in predicting HDP in the general pregnant population. A randomized controlled trial demonstrated that HBPM can help reduce prenatal checkups without increasing maternal anxiety [35]. Our method may contribute to safely omitting prenatal HDP screening at medical institutions for low-risk pregnant women.

Our study also confirmed the feasibility of HBPM in pregnant women. In our study, the participants in the validation cohort measured blood pressure on 86.2% of the days within the approximately six-month measurement period (Supplementary Table 1). The good adherence was probably due to the ease of HBPM. Interestingly, there was a slight improvement in measurement frequency in the validation cohort compared to the development cohort. A possible reason could be that, in the

validation cohort, we used a commercially available blood pressure monitor integrated with a dedicated smartphone app provided by the manufacturer. The smartphone app was useful for the participants to check their blood pressure history and to show it to clinical staff during prenatal checkups, which may have helped to maintain motivation. The accuracy of HBPM and the reduction of white coat effects have also been confirmed (Supplementary Figure 1).

It is generally expected that HBPM can detect increases in blood pressure earlier than OBPM. A previous study reported that the first episode of HBP $\geq$ 140/90 mmHg occurred approximately one month (median: 29 days) before clinical hypertension diagnosis [36]. However, our data showed no significant difference between the time when HBP and OBP first exceeded 140/90 mmHg (development cohort: median difference, 0 day; IQR, -8.5 to 5 days, p=0.67, Wilcoxon test; validation cohort: median difference, 1 day; IQR, -3 to 19 days, p=0.50, Wilcoxon test). This discrepancy may be due to white coat effects; some participants had a consistent increase of 10 mmHg or more in OBP compared with HBP. In addition, the TMM BirThree Cohort Study showed that both HBP and research BP were significantly lower than OBP [37], which may have influenced the timing of hypertension detection in our setting.

Our study has some limitations. First, this study is an observational study, not an intervention study. It is an important future work to evaluate the effectiveness of early interventions based on our prediction model, such as lifestyle modifications and drug treatments under medical supervision. Second, our study was based only on pregnant women in Toyama and Miyagi prefectures in Japan, limiting the generalizability of our findings. Future studies on more diverse populations are needed to expand the applicability of our model. Third, our prediction method has not been fully automated. Integrating our model into existing devices, software, and platforms, such as blood pressure monitors, smart phone apps, and cloud services, could facilitate the use of our model. Finally, our model has low PPV within four weeks in our validation cohort. To refine the prediction model, parameter optimization using larger data is needed. In addition, incorporating maternal demographic characteristics and medical history could potentially improve the predictive accuracy of the model.

Perspectives

In this study, we developed a machine-learning prediction method for HDP based on HBPM and verified its effectiveness. Especially, our method consistently exhibited high NPV values, and thus it would be useful to screen out normotensive individuals, which may contribute to reducing medical consultations. Further studies are needed to determine whether it is effective to start interventions in pregnant women at the time when the HDP onset is predicted by the prediction model. In addition, integrating the prediction model into blood pressure monitors, smart phone apps, and cloud services is another important future work. We hope that HBPM will become the standard for pregnant women in the near future, and that accurate prediction of HDP based on HBPM and appropriate early interventions will save both maternal and neonatal health.

Novelty and Relevance [92/100 words]

What Is New?
- A machine-learning prediction method for hypertensive disorders of pregnancy based on home blood pressure monitoring was developed.
- Its performance was validated in a separate cohort.

What Is Relevant?
- The proposed method does not require blood sampling at medical institutions, providing a convenient and practical method for predicting hypertensive disorders of pregnancy.
- The negative predictive value for prediction within one week was greater than 99%.

Clinical/Pathophysiological Implications?
- The proposed method would be especially useful to screen out low risk individuals, contributing to reducing medical consultations.

Acknowledgements
We would like to thank the study participants and clinical staff for their efforts in data collection.

Sources of Funding
This research was supported by JST Moonshot R&D Grant Number JPMJMS2021 and JSPS KAKENHI Grant Number JP25K02891. The BOSHI study was supported by MEXT/JSPS KAKENHI Grant Numbers JP16H05243, JP17K15857, JP18390192, JP18590587, JP18K15837, JP19H03905, JP19K18659, JP21390201, JP21K10438, JP24689061, JP25253059, and JP26860412; MHLW Program Grant Number JPMH19DA1001 and H21-Junkankitou [Seishuu]-Ippan-004; Children and Families Agency Program Grant Numbers JPCA23DA0601 and JPCA24DA0101; AMED Grant Numbers JP19gk0110039 and JP24gn0110088; a Grant-in-Aid for JSPS Fellows (19.7152).

Disclosures
For all authors, no potential conflicts of interest relevant to this study were reported. However, the following may represent potential conflicts of interest: HM received academic contributions from the J&J Medical Research Grant; HM received scholarship donations from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; HM concurrently holds a non-compensated sub-directorship position at the Tohoku Institute for Management of Blood Pressure, supported by Omron Health Care Co. Ltd., and is involved in collaborative research with Omron Health Care in another study.

Author contributions

Conceptualization: HM, SS. Methodology: SO. Software: MO, SO. Formal Analysis: MO, SO. Investigation: HM, EA, MI, AS, AN, RT, SY, NY, STs, STa, KH, KT, MY. Data Curation: MO, SO, HM, EA, MI, RT. Writing – Original Draft: MO. Writing – Review & Editing: All authors. Supervision: SS. Funding acquisition: HM, SS.

References

1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391-403.
2. Metoki H, Iwama N, Hamada H, Satoh M, Murakami T, Ishikuro M, Obara T. Hypertensive disorders of pregnancy: definition, management, and out-of-office blood pressure measurement. Hypertens Res. 2022;45(8):1298-1309.
3. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, Kenny LC, McCarthy F, Myers J, Poon LC, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148-169.
4. Croke L. Gestational Hypertension and Preeclampsia: A Practice Bulletin from ACOG. Am Fam Physician. 2019;100(10):649-650.
5. Combs CA, Montgomery DM. Society for Maternal-Fetal Medicine Special Statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin. Am J Obstet Gynecol. 2020;223(3):B7-B11.
6. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102(1):181-192.
7. Saudan P, Brown MA, Buddle ML, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol. 1998;105(11):1177-1184.
8. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension. 2009;53(5):812-818.
9. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32(3):171-178.
10. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15.
11. Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int. 2014;2014:297397.
12. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015;213(1):62.e1-62.e10.

13. O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.e1-103.e12.

14. Skråstad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KÅ. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG. 2015;122(13):1781-178.

15. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22.

16. Bian X, Biswas A, Huang X, Lee KJ, Li TK, Masuyama H, Ohkuchi A, Park JS, Saito S, Tan KH, et al. Short-Term Prediction of Adverse Outcomes Using the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio in Asian Women With Suspected Preeclampsia. Hypertension. 2019;74(1):164-172.

17. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, Nishiyama A, Aihara A, Sekino M, Kikuya M, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16(7):971-975.

18. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden T, et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24(12):779-785.

19. Suzuki Y, Matsubara K, Watanabe K, Tanaka K, Yamamoto T, Nohira T, Mimura K, Suzuki H, Hamada F, Makino S, et al. A multicenter prospective study of home blood pressure measurement (HBPM) during pregnancy in Japanese women. Hypertens Res. 2022;45(10):1563-1574.

20. Atluri N, Beyuo TK, Oppong SA, Compton SD, Moyer CA, Lawrence ER. Benefits and barriers of home blood pressure monitoring in pregnancy: perspectives of obstetric doctors from a Ghanaian tertiary hospital. BMC Pregnancy Childbirth. 2023;23(1):42.

21. Metoki H, Ohkubo T, Watanabe Y, Nishimura M, Sato Y, Kawaguchi M, Hara A, Hirose T, Obara T, Asayama K, et al. Seasonal trends of blood pressure during pregnancy in Japan: the babies and their parents' longitudinal observation in Suzuki Memorial Hospital in Intrauterine Period study. J Hypertens. 2008;26(12):2406-2413.

22. Metoki H, Ohkubo T, Obara T, Akutsu K, Yamamoto M, Ishikuro M, Sakurai K, Iwama N, Katagiri M, Sugawara J, et al. Daily serial hemodynamic data during pregnancy and seasonal variation: the BOSHI study. Clin Exp Hypertens. 2012;34(4):290-296.

23. Ishikuro M, Obara T, Metoki H, Ohkubo T, Yamamoto M, Akutsu K, Sakurai K, Iwama N, Katagiri M, Yagihashi K, et al. Blood pressure measured in the clinic and at home during pregnancy among nulliparous and multiparous women: the BOSHI study. Am J Hypertens. 2013;26(1):141-148.

24. Iwama N, Metoki H, Ohkubo T, Ishikuro M, Obara T, Kikuya M, Yagihashi K, Nishigori H, Sugiyama T, Sugawara J, et al. Maternal clinic and home blood pressure measurements during pregnancy and infant birth weight: the BOSHI study. Hypertens Res. 2016;39(3):151-157.

25. Iwama N, Oba MS, Satoh M, Ohkubo T, Ishikuro M, Obara T, Sasaki S, Saito M, Murakami Y, Kuriyama SI, et al. Association of maternal home blood pressure trajectory during pregnancy with infant birth weight: the BOSHI study. Hypertens Res. 2020;43(6):550-559.

26. Izumi S, Iwama N, Hamada H, Obara T, Ishikuro M, Satoh M, Murakami T, Saito M, Ohkubo T, Sugiyama T, et al. Associations of fasting plasma glucose and glycosylated hemoglobin levels at less than 24 weeks of gestation with hypertensive disorders of pregnancy: the BOSHI study. Endocr J. 2024;71(10):979-993.

27. Tsuji I, Imai Y, Nagai K, Ohkubo T, Watanabe N, Minami N, Itoh O, Bando T, Sakuma M, Fukao A, et al. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens. 1997;10(4 Pt 1):409-418.

28. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235-1481.

29. Mikami Y, Takai Y, Era S, Ono Y, Saitoh M, Baba K, Suzuki H, Seki H. Provisional criteria for the diagnosis of hypertension in pregnancy using home blood pressure measurements. Hypertens Res. 2017;40(7):679-684.

30. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic models: what, why, how, when and where? Clin Kidney J. 2020;14(1):49-58.

31. Collins GS, Dhiman P, Ma J, Schlussel MM, Archer L, Van Calster B, Harrell FE Jr, Martin GP, Moons KGM, van Smeden M, et al. Evaluation of clinical prediction models (part 1): from development to external validation. BMJ. 2024;384:e074819.

32. Hsieh CY, Chang WL, Hsiao CH, Yeong-Sung Lin F, Yu PC, Hung CW, Cheng HM. Machine learning of home blood pressure to predict short-term and long-term cardiovascular outcomes. Blood Press Monit. 2022;27(Suppl 1):e9.

33. Tucker KL, Hinton L, Green M, Chappell LC, McManus RJ. Using self-monitoring to detect and manage raised blood pressure and pre-eclampsia during pregnancy: the BUMP research programme and its impact. Hypertens Res. 2024;47(3):714-720.

34. Muijsers HEC, Wu P, van der Heijden OWH, Wijnberger LDE, van Bijsterveldt C, Buijs C, Pagels J, Tönnies P, Heiden S, Roeleveld N, et al. Home blood pressure monitoring detects unrevealed hypertension in women with a history of preeclampsia: Results of the BP-PRESELF study. Am J Prev Cardiol. 2022;12:100429.

35. Ross-McGill H, Hewison J, Hirst J, Dowswell T, Holt A, Brunskill P, Thornton JG. Antenatal home blood pressure monitoring: a pilot randomised controlled trial. BJOG. 2000;107(2):217-221.

36. Tucker KL, Mort S, Yu LM, Campbell H, Rivero-Arias O, Wilson HM, Allen J, Band R, Chisholm A, Crawford C, et al. Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial. JAMA. 2022;327(17):1656-1665.

37. Usuzaki T, Ishikuro M, Metoki H, Murakami K, Noda A, Ueno F, Kikuya M, Obara T, Kuriyama S. Comparison among research, home, and office blood pressure measurements for pregnant women: The TMM BirThree Cohort Study. J Clin Hypertens (Greenwich). 2020;22(11):2004-2013.

A Development cohort
(Miyagi, 2006-2011)

Total participants (n=1292)
NBPs 1051, HDPs 241

Excluded
• Multiple pregnancy (n=14)
• Insufficient measurements (n=835)

Analysis target (n=443)
NBPs 378, HDPs 65

Training data (n=365)
NBPs 339, HDPs 26

Test data (n=78), matched
NBPs 39, HDPs 39

B Validation cohort
(Toyama & Miyagi, 2021-2023)

Total participants (n=310)
NBPs 264, HDPs 46
(Toyama: NBPs 106, HDPs 25)
(Miyagi: NBPs 158, HDPs 21)

Excluded
• Multiple pregnancy (n=1)
• Induced abortion (n=3)
• Insufficient measurements (n=42)

Validation data (n=264)
NBPs 231, HDPs 33
(Toyama: NBPs 98, HDPs 21)
(Miyagi: NBPs 133, HDPs 12)

Figure 1. Flow chart. (A) Development cohort. (B) Validation cohort. NBP: normal blood pressure; HDP: hypertensive disorders of pregnancy.

A Training data (n=365)
AUC=0.949 (CI: 0.890-1.000)

B Test data (n=78)
AUC=0.884 (CI: 0.807-0.961)

C Validation data (n=264)
AUC=0.845 (CI: 0.759-0.930)

Figure 2. Receiver operating characteristic curves. (A) Training data. (B) Test data. (C) Validation data. AUC: area under the curve; CI: confidence interval.

Table 1. Baseline characteristics of the participants.

Item	Development cohort (NBPs)	Development cohort (HDPs)	Development cohort (p-value)	Validation cohort (NBPs)	Validation cohort (HDPs)	Validation cohort (p-value)
Participants (n)	378 (85.3%)	65 (14.7%)	-	231 (87.5%)	33 (12.5%)	-
Age (year)	32.0 (28.0-35.0)	34.0 (29.0-36.0)	0.051	33.0 (29.0-37.0)	34.0 (32.0-38.0)	0.074
Prepregnancy BMI (kg/m^2)	20.6 (19.4-22.8)	21.8 (19.8-24.5)	0.028	21.6 (19.5-24.2)	23.4 (20.7-28.3)	0.029
Prepregnancy obesity (n)	45 (11.9%)	15 (23.1%)	0.025	45 (19.5%)	13 (39.4%)	0.018
SBP (mmHg)[1]	104.0 (98.0-110.0)	111.0 (106.0-117.0)	2.3×10^{-9}	99.0 (92.0-106.0)	107.0 (99.0-113.0)	0.0010
DBP (mmHg)[1]	63.0 (58.0-68.0)	70.0 (65.0-75.0)	3.1×10^{-9}	67.0 (62.0-72.0)	75.0 (71.0-79.0)	3.0×10^{-5}
Smoking, past (n)	55 (14.6%)	9 (13.8%)	0.97	25 (10.8%)	1 (3.0%)	0.27
Smoking, current (n)	12 (3.2%)	2 (3.1%)	0.73	1 (0.4%)	0 (0.0%)	0.26
Nullipara (n)	160 (42.3%)	27 (41.5%)	0.99	69 (29.9%)	11 (33.3%)	0.84
Multipara with past HDP history (n)	8 (2.1%)	4 (6.2%)	0.15	15 (6.5%)	7 (21.2%)	0.012
Parent history of hypertension (n)	141 (37.3%)	31 (47.7%)	0.15	84 (36.4%)	14 (42.4%)	0.63
Parent history of diabetes (n)	63 (16.7%)	8 (12.3%)	0.48	31 (13.4%)	3 (9.1%)	0.68

Numerical data are presented as median and interquartile range. Prepregnancy obesity: prepregnancy BMI (body mass index) $\geq$ 25 kg/m^2. NBP: normal blood pressure; HDP: hypertensive disorders of pregnancy; SBP: systolic blood pressure; DBP: diastolic blood pressure.

[1]The SBP and DBP values shown are from the first home blood pressure measurement.

Table 2. Prediction performance of the proposed method.

	Sensitivity	Specificity	PPV	NPV	PLR	NLR
Development cohort, training (n=365)	0.923 (0.749-0.991)	0.888 (0.849-0.919)	0.387 (0.266-0.519)	0.993 (0.976-0.999)	8.235 (5.983-11.33)	0.087 (0.023-0.328)
Development cohort, test (n=78)	0.667 (0.498-0.809)	0.897 (0.758-0.971)	0.867 (0.693-0.962)	0.729 (0.582-0.847)	6.500 (2.502-16.88)	0.371 (0.235-0.586)
Development cohort, all (n=443)	0.769 (0.648-0.865)	0.889 (0.853-0.919)	0.543 (0.436-0.648)	0.957 (0.930-0.976)	6.923 (5.054-9.483)	0.260 (0.166-0.405)
Validation cohort, Toyama (n=119)	0.762 (0.528-0.918)	0.776 (0.680-0.854)	0.421 (0.263-0.592)	0.938 (0.862-0.980)	3.394 (2.188-5.264)	0.307 (0.142-0.665)
Validation cohort, Miyagi (n=145)	0.750 (0.428-0.945)	0.759 (0.678-0.829)	0.220 (0.106-0.376)	0.971 (0.918-0.994)	3.117 (1.998-4.863)	0.329 (0.123-0.881)
Validation cohort, all (n=264)	0.758 (0.577-0.889)	0.766 (0.706-0.819)	0.316 (0.216-0.431)	0.957 (0.917-0.981)	3.241 (2.394-4.387)	0.316 (0.172-0.581)

The 95% confidence intervals are in parentheses. PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio.

Table 3. Prediction performance of the proposed method for predictions within one week or four weeks.

	NPV (within 1 w)	Sensitivity (within 1 w)	Specificity (within 1 w)	PPV (within 4 w)	Sensitivity (within 4 w)	Specificity (within 4 w)
Development cohort, training (n=365)	0.999 (0.998-0.999)	0.733 (0.687-0.776)	0.970 (0.969-0.972)	0.299 (0.282-0.317)	0.657 (0.629-0.684)	0.976 (0.975-0.977)
Development cohort, test (n=78)	0.983 (0.981-0.985)	0.470 (0.424-0.517)	0.918 (0.914-0.923)	0.407 (0.381-0.432)	0.341 (0.318-0.363)	0.938 (0.934-0.942)
Development cohort, all (n=443)	0.996 (0.996-0.997)	0.593 (0.559-0.626)	0.962 (0.961-0.963)	0.338 (0.323-0.352)	0.469 (0.451-0.487)	0.971 (0.969-0.972)
Validation cohort, Toyama (n=119)	0.997 (0.996-0.998)	0.657 (0.571-0.736)	0.902 (0.897-0.906)	0.184 (0.165-0.203)	0.543 (0.501-0.585)	0.913 (0.908-0.917)
Validation cohort, Miyagi (n=145)	0.999 (0.998-0.999)	0.733 (0.619-0.829)	0.927 (0.923-0.931)	0.148 (0.129-0.168)	0.639 (0.582-0.693)	0.935 (0.931-0.938)
Validation cohort, all (n=264)	0.998 (0.997-0.998)	0.684 (0.617-0.746)	0.915 (0.912-0.918)	0.168 (0.154-0.182)	0.577 (0.543-0.610)	0.924 (0.921-0.927)

The 95% confidence intervals are in parentheses. NPV: negative predictive value; PPV: positive predictive value.